This activity expired on August 8, 2024; credit is no longer available.

Selective, Potent, Different: How to Enhance Clinical Benefits With Next-Generation ROS1 and TRK Inhibition in Treatment-Naïve and Pretreated NSCLC and Other Tumors

Media: Enduring Material
Activity Release Date: August 9, 2023
Activity Expiration Date: August 8, 2024
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in oncology discusses the latest advances with next-generation ROS1 and TRK inhibitors in treatment-naïve and pretreated ROS1 or NTRK fusion–positive NSCLC and other tumors, and provides practical, case-based guidance on how to incorporate these agents into management plans in the context of clinical practice and ongoing trials.

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, nurses, advanced practice clinicians, and other healthcare professionals involved in the care of patients with NSCLC and other solid tumors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Discuss the structure, characteristics, and mechanisms of action of novel tyrosine kinase inhibitors (TKIs) and their role in the treatment of ROS1/NTRK fusion–positive NSCLC and other solid tumors
• Implement best practices for biomarker testing to identify patients with ROS1/NTRK fusion–positive NSCLC or other solid tumors who might benefit from novel TKIs
• Select optimal therapy for individual patients with newly-diagnosed or TKI-resistant ROS1/NTRK fusion–positive NSCLC or other solid tumors in the context of clinical practice or clinical trial participation

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center (MSK)
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 14ner/Elevation Oncology; AbbVie; Amgen; ArcherDX, Inc.; AstraZeneca; BeiGene; BerGenBio ASA; Blueprint Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EcoR1; EMD Serono; Entos, Inc.; Exelixis, Inc.; Helsinn Healthcare SA; Hengrui Therapeutics, Inc.; Ignyta/Genentech, Inc./F. Hoffmann-La Roche, Ltd.; Janssen Pharmaceuticals, Inc.; Loxo Oncology/Bayer Corporation/Eli Lilly and Company; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; Novartis Pharmaceuticals Corporation; Nuvalent; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals, Inc./Millennium Pharmaceuticals, Inc.; Treeline Biosciences, Inc.; Turning Point Therapeutics; and Tyra Biosciences, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Grant Support paid to Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer; PharmaMar; Taiho Oncology, Inc; and Teva Pharmaceuticals USA, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 8/8/2024. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on August 8, 2024; credit is no longer available.

Selective, Potent, Different: How to Enhance Clinical Benefits With Next-Generation ROS1 and TRK Inhibition in Treatment-Naïve and Pretreated NSCLC and Other Tumors

Media: Enduring Material
Activity Release Date: August 9, 2023
Activity Expiration Date: August 8, 2024
Time to Complete Activity: 60 minutes

Activity Description

In this activity, an expert in oncology discusses the latest advances with next-generation ROS1 and TRK inhibitors in treatment-naïve and pretreated ROS1 or NTRK fusion–positive NSCLC and other tumors, and provides practical, case-based guidance on how to incorporate these agents into management plans in the context of clinical practice and ongoing trials.

Target Audience

This activity has been designed to meet the educational needs of oncologists, pathologists, nurses, advanced practice clinicians, and other healthcare professionals involved in the care of patients with NSCLC and other solid tumors.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Discuss the structure, characteristics, and mechanisms of action of novel tyrosine kinase inhibitors (TKIs) and their role in the treatment of ROS1/NTRK fusion–positive NSCLC and other solid tumors
• Implement best practices for biomarker testing to identify patients with ROS1/NTRK fusion–positive NSCLC or other solid tumors who might benefit from novel TKIs
• Select optimal therapy for individual patients with newly-diagnosed or TKI-resistant ROS1/NTRK fusion–positive NSCLC or other solid tumors in the context of clinical practice or clinical trial participation

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Alexander Drilon, MD
Chief, Early Drug Development
Memorial Sloan Kettering Cancer Center (MSK)
New York, New York

Alexander Drilon, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 14ner/Elevation Oncology; AbbVie; Amgen; ArcherDX, Inc.; AstraZeneca; BeiGene; BerGenBio ASA; Blueprint Medicines Corporation; Chugai Pharmaceutical Co., Ltd.; EcoR1; EMD Serono; Entos, Inc.; Exelixis, Inc.; Helsinn Healthcare SA; Hengrui Therapeutics, Inc.; Ignyta/Genentech, Inc./F. Hoffmann-La Roche, Ltd.; Janssen Pharmaceuticals, Inc.; Loxo Oncology/Bayer Corporation/Eli Lilly and Company; Merus; Monopteros Therapeutics; Monte Rosa Therapeutics; Novartis Pharmaceuticals Corporation; Nuvalent; Pfizer; Prelude Therapeutics; Repare Therapeutics; Takeda Pharmaceutical Company Limited/ARIAD Pharmaceuticals, Inc./Millennium Pharmaceuticals, Inc.; Treeline Biosciences, Inc.; Turning Point Therapeutics; and Tyra Biosciences, Inc.
Grant/Research Support from Foundation Medicine, Inc. *Grant Support paid to Institution: Exelixis, Inc.; GlaxoSmithKline; Pfizer; PharmaMar; Taiho Oncology, Inc; and Teva Pharmaceuticals USA, Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 8/8/2024. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on August 1, 2024; credit is no longer available.

Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy

Media: Enduring Material
Activity Release Date: August 2, 2023
Activity Expiration Date: August 1, 2024
Time to Complete Activity: 60 minutes

Activity Description

Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care.

Target Audience

This activity has been designed to meet the educational needs of hematologists, oncologists, hematology-oncologists, pathologists, nurses, pharmacists, and other clinicians involved in the care of patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
• Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions
• Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors
• Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Jennifer Woyach, MD
Professor of Internal Medicine
Division of Hematology
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Jennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.
Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

The activity titled “Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-054-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on August 1, 2024; credit is no longer available.

Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy

Media: Enduring Material
Activity Release Date: August 2, 2023
Activity Expiration Date: August 1, 2024
Time to Complete Activity: 60 minutes

Activity Description

Learn how CLL expert Jennifer Woyach, MD, employs patient treatment history, prognostic information, and other clinically relevant factors to develop comprehensive treatment plans for her patients and get up to date on the latest evidence with BTK inhibitors for CLL by participating in this video activity. Dr. Woyach will focus on enhancing your understanding of the mechanistic, selectivity, and safety differences between covalent and non-covalent BTK inhibitors (BTKi) and BCL2 inhibitors (BCL2i), the mechanisms of intolerance and BTK resistance, and how BTKi fit into personalized treatment plans informed by the use of validated techniques such as next-generation sequencing, FISH, and karyotype testing. Learners will also be exposed to resources from the CLL Society that can be used to help educate patients on the latest therapeutic advances in customized CLL care.

Target Audience

This activity has been designed to meet the educational needs of hematologists, oncologists, hematology-oncologists, pathologists, nurses, pharmacists, and other clinicians involved in the care of patients with CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
• Cite validated techniques, including next-generation sequencing, to identify prognostic and predictive markers such as del(17p)/TP53, BTK mutations, and minimal residual disease status to inform treatment decisions
• Develop team-based management strategies that include patient treatment history, prognostic information, and other clinically relevant factors
• Implement team-based strategies to educate patients on their prognosis, facilitate clinical trial enrollment, and address dosing and safety considerations when using BTKi strategies

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Jennifer Woyach, MD
Professor of Internal Medicine
Division of Hematology
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Jennifer Woyach, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for ArQule, Inc.; AstraZeneca; BeiGene; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Loxo Oncology; Newave Pharmaceutical Inc; and Pharmacyclics LLC.
Grant/Research Support from AstraZeneca; Karyopharm Therapeutics; Loxo Oncology; MingSight Pharmaceuticals, Inc.; MorphoSys US Inc.; Schrödinger, Inc.; and Verastem Oncology.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Continuing Certification Statement

The activity titled “Taking Direction From Biomarkers and Prognostic Factors in CLL: Interprofessional Strategies for Addressing Challenges With Continuous BTKi Therapy” has been registered to offer 1.0 Lifelong Learning credit in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-054-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/CC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on June 28, 2024; credit is no longer available.

Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider

Media: Enduring Material
Activity Release Date: June 29, 2023
Activity Expiration Date: June 28, 2024
Time to Complete Activity: 45 minutes

Activity Description

In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum.

Target Audience

This activity has been designed to meet the educational needs of healthcare professionals who treat, care for, and/or support people living with HIV.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Identify individual and structural factors that contribute to PLWH falling out of care
• Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
• Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Allison Agwu, MD, ScM, FAAP, FIDSA
Professor of Pediatrics and Internal Medicine
Division of Infectious Diseases
Program Director, Pediatric Adolescent Young Adult HIV/AIDS Program
Medical Director, Accessing Care Early (ACE) Clinic
Johns Hopkins University School of Medicine
Baltimore, Maryland

Allison Agwu, MD, ScM, FAAP, FIDSA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co., Inc.

Faculty/Planner
Nara Lee, LICSW
Social Work & Clinical Services Manager
HIV Prevention and Treatment Services
Special Immunology Services
Children’s National Hospital
Washington, DC

Nara Lee, LICSW, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
David Martin
Patient/Advocate

David Martin has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Shawnte' Spriggs
Patient/Advocate

Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-046-H02-P
Type of Activity: Knowledge

Health Education Specialists

Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES^®) and/or Master Certified Health Education Specialists (MCHES^®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/CECH Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on June 28, 2024; credit is no longer available.

Retaining and Re-Engaging People Living With HIV in Care: A Unique Look at Challenges and Opportunities From the Perspective of the Patient, Navigator, and Provider

Media: Enduring Material
Activity Release Date: June 29, 2023
Activity Expiration Date: June 28, 2024
Time to Complete Activity: 45 minutes

Activity Description

In this activity, an expert provider, navigator, and two patients explore the factors that contribute to people living with HIV (PLWH) falling out of care and different strategies that can be used for re-engaging PLWH back into the HIV care continuum.

Target Audience

This activity has been designed to meet the educational needs of healthcare professionals who treat, care for, and/or support people living with HIV.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Identify individual and structural factors that contribute to PLWH falling out of care
• Discuss methodologies, benefits, and limitations associated with different strategies for re-engaging PLWH who are out of care
• Employ individualized and comprehensive plans to successfully re-engage PLWH in care

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Allison Agwu, MD, ScM, FAAP, FIDSA
Professor of Pediatrics and Internal Medicine
Division of Infectious Diseases
Program Director, Pediatric Adolescent Young Adult HIV/AIDS Program
Medical Director, Accessing Care Early (ACE) Clinic
Johns Hopkins University School of Medicine
Baltimore, Maryland

Allison Agwu, MD, ScM, FAAP, FIDSA, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Gilead Sciences, Inc.; Merck & Co., Inc.; and ViiV Healthcare.
Grant/Research Support from Gilead Sciences, Inc. and Merck & Co., Inc.

Faculty/Planner
Nara Lee, LICSW
Social Work & Clinical Services Manager
HIV Prevention and Treatment Services
Special Immunology Services
Children’s National Hospital
Washington, DC

Nara Lee, LICSW, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
David Martin
Patient/Advocate

David Martin has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Shawnte' Spriggs
Patient/Advocate

Shawnte' Spriggs has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthHIV. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Gilead Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and no contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-046-H02-P
Type of Activity: Knowledge

Health Education Specialists

Sponsored by PVI, PeerView Institute for Medical Education, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES^®) and/or Master Certified Health Education Specialists (MCHES^®) to receive up to 0.75 total Category 1 continuing education contact hours. Maximum advanced-level continuing education contact hours are 0.0. Continuing Competency credits available are 0.0.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/CECH Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on June 12, 2024; credit is no longer available.

Can We Improve Management of Overactive Bladder in Long-Term Care? Examining the Role of Beta-3 Adrenergic Agonists

Media: Enduring Material
Activity Release Date: June 13, 2023
Activity Expiration Date: June 12, 2024
Time to Complete Activity: 60 minutes

Activity Description

Overactive bladder is frequently underdiagnosed and undertreated, but fortunately there's a newer treatment option with the beta-3 adrenoreceptor agonists. This class demonstrates efficacy without anticholinergic adverse effects, enabling you to provide optimal, patient-centered care for residents of long-term care facilities.

This PeerView educational activity is designed to help improve your ability to accurately recognize overactive bladder, apply appropriate diagnostic criteria, and incorporate newer treatment options. Expert faculty explain the clinically relevant ways in which the newer beta-3 adrenoreceptor agonists differ from traditional antimuscarinics, as well as how they differ from each other with regard to selectivity and safety.

Target Audience

This activity has been designed to meet the educational needs of geriatricians, urologists, family practitioners, advanced practice clinicians (NPs/PAs), nurses, and other healthcare professionals involved in the care of patients with overactive bladder.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Recognize the individual, clinical, and economic burdens of OAB specific to patients living in long-term care facilities
• Engage members of the healthcare team to routinely screen long-term care residents for symptoms of OAB
• Apply recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomatology
• Implement individualized OAB treatment plans that minimize risks related to cardiovascular health, cognitive impairment and dementia, and polypharmacy concerns

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Benjamin M. Brucker, MD
Director, Division of Female Pelvic Medicine & Reconstructive Surgery and Neurourology
Program Director, FPMRS Fellowship
Departments of Urology and Obstetrics & Gynecology
New York University
Langone Health
New York, New York

Benjamin M. Brucker, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Palette Life Sciences, Inc.; Urovant Sciences Inc.; and Watkins-Conti Products.
Speaker for AbbVie Inc.; Antares Pharma, Inc.; and Urovant Sciences Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Urovant Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 6/12/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on June 12, 2024; credit is no longer available.

Can We Improve Management of Overactive Bladder in Long-Term Care? Examining the Role of Beta-3 Adrenergic Agonists

Media: Enduring Material
Activity Release Date: June 13, 2023
Activity Expiration Date: June 12, 2024
Time to Complete Activity: 60 minutes

Activity Description

Overactive bladder is frequently underdiagnosed and undertreated, but fortunately there's a newer treatment option with the beta-3 adrenoreceptor agonists. This class demonstrates efficacy without anticholinergic adverse effects, enabling you to provide optimal, patient-centered care for residents of long-term care facilities.

This PeerView educational activity is designed to help improve your ability to accurately recognize overactive bladder, apply appropriate diagnostic criteria, and incorporate newer treatment options. Expert faculty explain the clinically relevant ways in which the newer beta-3 adrenoreceptor agonists differ from traditional antimuscarinics, as well as how they differ from each other with regard to selectivity and safety.

Target Audience

This activity has been designed to meet the educational needs of geriatricians, urologists, family practitioners, advanced practice clinicians (NPs/PAs), nurses, and other healthcare professionals involved in the care of patients with overactive bladder.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Recognize the individual, clinical, and economic burdens of OAB specific to patients living in long-term care facilities
• Engage members of the healthcare team to routinely screen long-term care residents for symptoms of OAB
• Apply recommended diagnostic criteria to differentiate OAB from other urinary conditions with shared symptomatology
• Implement individualized OAB treatment plans that minimize risks related to cardiovascular health, cognitive impairment and dementia, and polypharmacy concerns

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Benjamin M. Brucker, MD
Director, Division of Female Pelvic Medicine & Reconstructive Surgery and Neurourology
Program Director, FPMRS Fellowship
Departments of Urology and Obstetrics & Gynecology
New York University
Langone Health
New York, New York

Benjamin M. Brucker, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Palette Life Sciences, Inc.; Urovant Sciences Inc.; and Watkins-Conti Products.
Speaker for AbbVie Inc.; Antares Pharma, Inc.; and Urovant Sciences Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Urovant Sciences, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 6/12/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on July 3, 2024; credit is no longer available.

Immunotherapy for the Win Against Melanoma: Strategies for Integrating Innovative and Next-Generation Immunotherapy Options

Media: Enduring Material
Activity Release Date: June 4, 2023
Activity Expiration Date: July 3, 2024
Time to Complete Activity: 90 minutes

Activity Description

In this activity, based on a recent symposium held during the 2023 ASCO Annual Meeting, leading experts guide you through the winning era of immunotherapy in melanoma. Through a series of linked lectures and debates, the panel discusses the integration of modern immunotherapy combination and sequential options in advanced disease and considers options for patients progressing on prior immunotherapy. They also examine new developments with immunotherapy in the adjuvant and neoadjuvant settings.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, surgical oncologists, dermatologists, advanced practice clinicians, and other clinicians involved in the care of patients with melanoma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Discuss current guidelines, efficacy, and safety data surrounding the use of immunotherapy in melanoma as neoadjuvant or adjuvant therapy in resectable disease or as part of novel combinatorial or sequential approaches for unresectable disease
• Craft team-based treatment plans that include immunotherapy for resectable and unresectable melanoma, including BRAF-mutant or BRAF wild-type disease, based on updated evidence and guideline recommendations
• Develop management strategies for the unique adverse events associated with immunotherapy for patients with melanoma across the spectrum of disease

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Jason J. Luke, MD, FACP
Interim Associate Director for Clinical Research
Director - Immunotherapy and Drug Development Center
Associate Professor of Medicine
UPMC Hillman Cancer Center and University of Pittsburgh
Pittsburgh, Pennsylvania

Jason J. Luke, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 7 Hills Pharma LLC; AbbVie Inc.; Actym Therapeutics, Inc.; Affivant Sciences, Inc.; Agenus Inc.; Alnylam Pharmaceuticals, Inc.; Alphamab Oncology; Arch Oncology; AstraZeneca; Atomwise Inc.; Bayer HealthCare Pharmaceuticals Inc.; BioCytics; Bright Peak Therapeutics; Bristol Myers Squibb; Castle Biosciences, Inc.; Checkmate Pharmaceuticals; Codiak BioSciences; Crown Pharmaceuticals; Cugene Inc.; Curadev; Day One Biopharmaceuticals, Inc.; Duke Street Bio Ltd; Exo Therapeutics, Inc.; Eisai Co., Ltd; EMD Serono; Endeavor Biomedicines; F-Star Therapeutics Inc.; Flame pharmaceuticals; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Glenmark Pharmaceuticals; HotSpot Therapeutics, Inc.; Ikena Oncology; Immatics US, Inc.; Immunocore Ltd; Incyte; Instil Bio; Inzen Therapeutics Inc.; IO Biotech; Janssen Pharmaceuticals, Inc.; Kadmon Corporation; KSQ Therapeutics, Inc.; Kanaph Therapeutics Inc; MacroGenics, Inc.; Mavu; Merck & Co., Inc.; Mersana Therapeutics Inc.; Nektar; NeoTX; Novartis Pharmaceuticals Corporation; Onc.AI; OncoNano Medicine; Partners Pharma; Pfizer; physIQ; Pioneering Medicines; PsiOxus; Pyxis Technologies Inc.; RefleXion; Regeneron Pharmaceuticals Inc.; Replimune Group Inc.; Ribon Therapeutics; Roivant Sciences Ltd; Saros Therapeutics; Servier Pharmaceuticals LLC; Stingthera, Inc.; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics, Inc.; and Xilio Therapeutics.
Grant/Research Support from AbbVie Inc.; Astellas Pharma Inc.; AstraZeneca; Bristol Myers Squibb; Corvus Pharmaceuticals; Day One Biopharmaceuticals, Inc.; EMD Serono; F-Star Therapeutics Inc.; Genmab A/S; HotSpot Therapeutics, Inc.; Ikena Oncology; Immatics US, Inc.; Incyte; Kadmon Corporation; KAHR; MacroGenics, Inc.; Merck & Co., Inc.; Moderna, Inc.; Nektar; NextCure, Inc.; Numab; Palleon Pharmaceuticals; Pfizer; Replimune Group Inc.; Rubius Therapeutics Inc.; Servier Pharmaceuticals LLC; Scholar Rock; Synlogic; Takeda Pharmaceutical Company; Trishula Therapeutics, Inc.; Tizona Therapeutics, Inc.; and Xencor.
Stock Shareholder in Actym Therapeutics, Inc.; Alphamab Oncology; Arch Oncology; Duke Street Bio Ltd; Kanaph Therapeutics Inc; Mavu; NeoTX; Onc.AI; OncoNano Medicine; physIQ; Pyxis Technologies Inc.; Saros Therapeutics; STipe Therapeutics; and Tempest Therapeutics, Inc.
Data Safety Monitoring Board for AbbVie Inc.; Agenus Inc.; Evaxion Biotech; and Immutep Limited.

Faculty/Planner
Kari Kendra, MD, PhD
Professor
Department of Internal Medicine, Division of Medical Oncology
Director, Cutaneous Oncology Program
Chair, Melanoma Disease Specific Research Committee
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Kari Kendra, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bristol Myers Squibb (institutional support); Checkmate Pharmaceuticals, Inc.; GlaxoSmithKline; Immunocore Ltd; Merck & Co., Inc.; Medpace; Novartis Pharmaceuticals Corporation; and Varian Medical Systems.

Faculty/Planner
Meredith McKean, MD, MPH
Director, Melanoma and Skin Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Meredith McKean, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Castle Biosciences, Inc.; Eisai Co., Ltd.; IQVIA Inc.; iTeos Therapeutics; Merck & Co., Inc.; Moderna, Inc.; and Pfizer.
Grant/Research Support from Aadi Bioscience, Inc.; Alpine Immune Sciences; Arcus Biosciences, Inc.; Arvinas; Ascentage Pharma; ASCO; Astellas Pharma Inc.; Bayer HealthCare Pharmaceuticals Inc.; Bicycle Therapeutics; BioMed Valley Discoveries, Inc.; BioNTech SE; C4 Therapeutics, Inc.; Dragonfly Therapeutics; EMD Serono; Epizyme, Inc.; Erasca, Inc.; Exelixis, Inc.; Foghorn Therapeutics; G1 Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; GSK; IDEAYA Biosciences; Ikena Oncology; ImmVira Pharma; Infinity Pharmaceuticals, Inc.; Jacobio Pharmaceuticals; Kechow Pharma; Kezar Life Sciences Inc.; Kinnate Biopharma Inc.; MedImmune; Mereo Biopharma Group PLC; Metabomed Ltd.; Moderna, Inc.; NBE-Therapeutics AG; Nektar; Novartis Pharmaceuticals Corporation; OncoC4; Oncorus, Inc.; PACT Pharma, Inc.; Pfizer; Plexxikon; Poseida Therapeutics, Inc.; Prelude Therapeutics; Pyramid Biosciences; Regeneron Pharmaceuticals Inc.; Sapience Therapeutics, Inc.; Scholar Rock; Seattle Genetics; Synthrox; Takeda Pharmaceutical Company; TeneoBio; Tempest Therapeutics, Inc.; Tizona Therapeutics, Inc.; Tmunity Therapeutics, Inc.; TopAlliance Biosciences; and Xilio Therapeutics.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from Merck & Co., Inc., and Regeneron Pharmaceuticals, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/3/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on July 3, 2024; credit is no longer available.

Immunotherapy for the Win Against Melanoma: Strategies for Integrating Innovative and Next-Generation Immunotherapy Options

Media: Enduring Material
Activity Release Date: June 4, 2023
Activity Expiration Date: July 3, 2024
Time to Complete Activity: 90 minutes

Activity Description

In this activity, based on a recent symposium held during the 2023 ASCO Annual Meeting, leading experts guide you through the winning era of immunotherapy in melanoma. Through a series of linked lectures and debates, the panel discusses the integration of modern immunotherapy combination and sequential options in advanced disease and considers options for patients progressing on prior immunotherapy. They also examine new developments with immunotherapy in the adjuvant and neoadjuvant settings.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, surgical oncologists, dermatologists, advanced practice clinicians, and other clinicians involved in the care of patients with melanoma.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Discuss current guidelines, efficacy, and safety data surrounding the use of immunotherapy in melanoma as neoadjuvant or adjuvant therapy in resectable disease or as part of novel combinatorial or sequential approaches for unresectable disease
• Craft team-based treatment plans that include immunotherapy for resectable and unresectable melanoma, including BRAF-mutant or BRAF wild-type disease, based on updated evidence and guideline recommendations
• Develop management strategies for the unique adverse events associated with immunotherapy for patients with melanoma across the spectrum of disease

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Jason J. Luke, MD, FACP
Interim Associate Director for Clinical Research
Director - Immunotherapy and Drug Development Center
Associate Professor of Medicine
UPMC Hillman Cancer Center and University of Pittsburgh
Pittsburgh, Pennsylvania

Jason J. Luke, MD, FACP, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for 7 Hills Pharma LLC; AbbVie Inc.; Actym Therapeutics, Inc.; Affivant Sciences, Inc.; Agenus Inc.; Alnylam Pharmaceuticals, Inc.; Alphamab Oncology; Arch Oncology; AstraZeneca; Atomwise Inc.; Bayer HealthCare Pharmaceuticals Inc.; BioCytics; Bright Peak Therapeutics; Bristol Myers Squibb; Castle Biosciences, Inc.; Checkmate Pharmaceuticals; Codiak BioSciences; Crown Pharmaceuticals; Cugene Inc.; Curadev; Day One Biopharmaceuticals, Inc.; Duke Street Bio Ltd; Exo Therapeutics, Inc.; Eisai Co., Ltd; EMD Serono; Endeavor Biomedicines; F-Star Therapeutics Inc.; Flame pharmaceuticals; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Glenmark Pharmaceuticals; HotSpot Therapeutics, Inc.; Ikena Oncology; Immatics US, Inc.; Immunocore Ltd; Incyte; Instil Bio; Inzen Therapeutics Inc.; IO Biotech; Janssen Pharmaceuticals, Inc.; Kadmon Corporation; KSQ Therapeutics, Inc.; Kanaph Therapeutics Inc; MacroGenics, Inc.; Mavu; Merck & Co., Inc.; Mersana Therapeutics Inc.; Nektar; NeoTX; Novartis Pharmaceuticals Corporation; Onc.AI; OncoNano Medicine; Partners Pharma; Pfizer; physIQ; Pioneering Medicines; PsiOxus; Pyxis Technologies Inc.; RefleXion; Regeneron Pharmaceuticals Inc.; Replimune Group Inc.; Ribon Therapeutics; Roivant Sciences Ltd; Saros Therapeutics; Servier Pharmaceuticals LLC; Stingthera, Inc.; STipe Therapeutics; Synlogic; Synthekine; Tempest Therapeutics, Inc.; and Xilio Therapeutics.
Grant/Research Support from AbbVie Inc.; Astellas Pharma Inc.; AstraZeneca; Bristol Myers Squibb; Corvus Pharmaceuticals; Day One Biopharmaceuticals, Inc.; EMD Serono; F-Star Therapeutics Inc.; Genmab A/S; HotSpot Therapeutics, Inc.; Ikena Oncology; Immatics US, Inc.; Incyte; Kadmon Corporation; KAHR; MacroGenics, Inc.; Merck & Co., Inc.; Moderna, Inc.; Nektar; NextCure, Inc.; Numab; Palleon Pharmaceuticals; Pfizer; Replimune Group Inc.; Rubius Therapeutics Inc.; Servier Pharmaceuticals LLC; Scholar Rock; Synlogic; Takeda Pharmaceutical Company; Trishula Therapeutics, Inc.; Tizona Therapeutics, Inc.; and Xencor.
Stock Shareholder in Actym Therapeutics, Inc.; Alphamab Oncology; Arch Oncology; Duke Street Bio Ltd; Kanaph Therapeutics Inc; Mavu; NeoTX; Onc.AI; OncoNano Medicine; physIQ; Pyxis Technologies Inc.; Saros Therapeutics; STipe Therapeutics; and Tempest Therapeutics, Inc.
Data Safety Monitoring Board for AbbVie Inc.; Agenus Inc.; Evaxion Biotech; and Immutep Limited.

Faculty/Planner
Kari Kendra, MD, PhD
Professor
Department of Internal Medicine, Division of Medical Oncology
Director, Cutaneous Oncology Program
Chair, Melanoma Disease Specific Research Committee
The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

Kari Kendra, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from Bristol Myers Squibb (institutional support); Checkmate Pharmaceuticals, Inc.; GlaxoSmithKline; Immunocore Ltd; Merck & Co., Inc.; Medpace; Novartis Pharmaceuticals Corporation; and Varian Medical Systems.

Faculty/Planner
Meredith McKean, MD, MPH
Director, Melanoma and Skin Cancer Research Program
Sarah Cannon Research Institute
Nashville, Tennessee

Meredith McKean, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Castle Biosciences, Inc.; Eisai Co., Ltd.; IQVIA Inc.; iTeos Therapeutics; Merck & Co., Inc.; Moderna, Inc.; and Pfizer.
Grant/Research Support from Aadi Bioscience, Inc.; Alpine Immune Sciences; Arcus Biosciences, Inc.; Arvinas; Ascentage Pharma; ASCO; Astellas Pharma Inc.; Bayer HealthCare Pharmaceuticals Inc.; Bicycle Therapeutics; BioMed Valley Discoveries, Inc.; BioNTech SE; C4 Therapeutics, Inc.; Dragonfly Therapeutics; EMD Serono; Epizyme, Inc.; Erasca, Inc.; Exelixis, Inc.; Foghorn Therapeutics; G1 Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; GSK; IDEAYA Biosciences; Ikena Oncology; ImmVira Pharma; Infinity Pharmaceuticals, Inc.; Jacobio Pharmaceuticals; Kechow Pharma; Kezar Life Sciences Inc.; Kinnate Biopharma Inc.; MedImmune; Mereo Biopharma Group PLC; Metabomed Ltd.; Moderna, Inc.; NBE-Therapeutics AG; Nektar; Novartis Pharmaceuticals Corporation; OncoC4; Oncorus, Inc.; PACT Pharma, Inc.; Pfizer; Plexxikon; Poseida Therapeutics, Inc.; Prelude Therapeutics; Pyramid Biosciences; Regeneron Pharmaceuticals Inc.; Sapience Therapeutics, Inc.; Scholar Rock; Seattle Genetics; Synthrox; Takeda Pharmaceutical Company; TeneoBio; Tempest Therapeutics, Inc.; Tizona Therapeutics, Inc.; Tmunity Therapeutics, Inc.; TopAlliance Biosciences; and Xilio Therapeutics.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from Merck & Co., Inc., and Regeneron Pharmaceuticals, Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/3/2024. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on July 2, 2024; credit is no longer available.

New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now

Activity Description and Educational Objectives

Recent research and improved understanding of the pathogenesis of multiple sclerosis (MS) has led to the development of multiple biomarkers and imaging modalities that can improve clinicians’ ability to individualize therapy through more effective monitoring of disease progression and treatment response. The promise of eventually arriving at data-driven personalized care—coupled with the number of available and emerging therapies for MS treatment—makes it more important than ever that clinicians remain up-to-date on advances in biomarkers and imaging approaches, as well as shared decision-making strategies.

In this activity, based on a recent live symposium, MS experts cover the latest data on these new and emerging biomarkers for MS management. Using examples from their own practice, the panelists also discuss ways to incorporate these biomarker findings into individualized treatment decisions to empower patients and improve treatment outcomes.

Upon completion of this activity, participants should be better able to:

• Describe emerging biomarkers that may play a role in evaluating MS disease activity, progression, and treatment response
• Individualize treatment decisions for patients with MS, incorporating biomarker findings, disease status, and other patient-specific characteristics
• Integrate team-based shared decision-making strategies to facilitate appropriate treatment selection, empower patients, and improve outcomes

Target Audience

This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE/IPCE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: June 3, 2023 - July 2, 2024
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.

Chair & Moderator
Jiwon Oh, MD, PhD, FRCPC
Medical Director, Barlo Multiple Sclerosis Program
Associate Professor, Division of Neurology
St. Michael’s Hospital
University of Toronto
Staff Neurologist
Scientist
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada

Jiwon Oh, MD, PhD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; Bristol Myers Squibb; EMD Serono Canada; F. Hoffmann-La Roche Ltd; Lilly; Novartis Pharmaceuticals Canada Inc.; and Sanofi/Genzyme Canada Inc.
Grant/Research Support from Biogen Canada Inc.; EMD Serono Canada; and F. Hoffmann-La Roche Ltd.
Speaker for Biogen Canada Inc.; Bristol Myers Squibb; EMD Serono Canada; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Canada Inc.; and Sanofi/Genzyme Canada Inc.

Presenters
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES
Professor
Departments of Clinical Pharmacy and Neurology
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado, Anschutz Medical Campus
Aurora, Colorado

Jacci Bainbridge, PharmD, FCCP, MSCS, FAES, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals Corporation.

Kathleen M. Costello, RN, MS, NP, MSCN
Chief Operating Officer
Can Do-Multiple Sclerosis
Avon, Colorado

Kathleen M. Costello, RN, MS, NP, MSCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6939-23-T.

Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-039-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on July 2, 2024; credit is no longer available.

New and Emerging Biomarkers in Patient-Centered MS Management: The Future of Personalized Patient Care Begins Now

Activity Description and Educational Objectives

Recent research and improved understanding of the pathogenesis of multiple sclerosis (MS) has led to the development of multiple biomarkers and imaging modalities that can improve clinicians’ ability to individualize therapy through more effective monitoring of disease progression and treatment response. The promise of eventually arriving at data-driven personalized care—coupled with the number of available and emerging therapies for MS treatment—makes it more important than ever that clinicians remain up-to-date on advances in biomarkers and imaging approaches, as well as shared decision-making strategies.

In this activity, based on a recent live symposium, MS experts cover the latest data on these new and emerging biomarkers for MS management. Using examples from their own practice, the panelists also discuss ways to incorporate these biomarker findings into individualized treatment decisions to empower patients and improve treatment outcomes.

Upon completion of this activity, participants should be better able to:

• Describe emerging biomarkers that may play a role in evaluating MS disease activity, progression, and treatment response
• Individualize treatment decisions for patients with MS, incorporating biomarker findings, disease status, and other patient-specific characteristics
• Integrate team-based shared decision-making strategies to facilitate appropriate treatment selection, empower patients, and improve outcomes

Target Audience

This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with multiple sclerosis.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD/CPE/IPCE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Media: Enduring Material
Release and Expiration Dates: June 3, 2023 - July 2, 2024
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are mitigated so that presentations are evidence-based and scientifically balanced.

Chair & Moderator
Jiwon Oh, MD, PhD, FRCPC
Medical Director, Barlo Multiple Sclerosis Program
Associate Professor, Division of Neurology
St. Michael’s Hospital
University of Toronto
Staff Neurologist
Scientist
Keenan Research Centre of the Li Ka Shing Knowledge Institute
Toronto, Ontario, Canada

Jiwon Oh, MD, PhD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; Bristol Myers Squibb; EMD Serono Canada; F. Hoffmann-La Roche Ltd; Lilly; Novartis Pharmaceuticals Canada Inc.; and Sanofi/Genzyme Canada Inc.
Grant/Research Support from Biogen Canada Inc.; EMD Serono Canada; and F. Hoffmann-La Roche Ltd.
Speaker for Biogen Canada Inc.; Bristol Myers Squibb; EMD Serono Canada; F. Hoffmann-La Roche Ltd; Novartis Pharmaceuticals Canada Inc.; and Sanofi/Genzyme Canada Inc.

Presenters
Jacci Bainbridge, PharmD, FCCP, MSCS, FAES
Professor
Departments of Clinical Pharmacy and Neurology
Skaggs School of Pharmacy and Pharmaceutical Sciences
University of Colorado, Anschutz Medical Campus
Aurora, Colorado

Jacci Bainbridge, PharmD, FCCP, MSCS, FAES, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Novartis Pharmaceuticals Corporation.

Kathleen M. Costello, RN, MS, NP, MSCN
Chief Operating Officer
Can Do-Multiple Sclerosis
Avon, Colorado

Kathleen M. Costello, RN, MS, NP, MSCN, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Novartis Pharmaceuticals Corporation.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

All of the relevant financial relationships listed for these individuals have been mitigated.

Accreditation, Credit, and Support

Penn State College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity is developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Penn State College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G6939-23-T.

Support

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-039-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, and Penn State College of Medicine are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Penn State College of Medicine.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on July 2, 2024; credit is no longer available.

Defying the Odds With Innovation in CLL: Perspectives on Personalized Care, Multiagent Platforms, and Sequential Strategies

Media: Enduring Material
Activity Release Date: June 3, 2023
Activity Expiration Date: July 2, 2024
Time to Complete Activity: 90 minutes

Activity Description

Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, physician assistants, nurse practitioners, and other clinicians involved in the management of patients with chronic lymphocytic leukemia.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics
• Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations
• Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL
• Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Matthew S. Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Co-Leader for Lymphoma of Dana-Farber/Harvard Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Matthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Ono Pharmaceutical Co., Ltd.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.
Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.
Honoraria from Aptitude Health; Bio Ascend; and Curio Science.
Other Financial or Material Support in the form of Royalties from Up-to-Date.

Faculty/Planner
Adam Scott Kittai, MD
Assistant Professor – Clinical, Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, Ohio

Adam Scott Kittai, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; and Lilly.
Grant/Research Support from AstraZeneca.
Speaker for AbbVie; BeiGene, Inc.; and Bristol Myers Squibb.

Faculty/Planner
Nicole Lamanna, MD
Associate Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, New York

Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.

Faculty/Planner
William G. Wierda, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine
D.B. Lane Cancer Research Distinguished Professor
Section Chief - Chronic Lymphocytic Leukemia
Center Medical Director
Executive Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas

William G. Wierda, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AbbVie; Acerta Pharma; Bristol Myers Squibb; Cyclacel Pharmaceuticals Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Biotech, Inc.; Juno Pharmaceuticals; Kite, A Gilead Company; Loxo Oncology, Inc.; miRagen Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncternal Therapeutics; Pharmacyclics, Inc.; Sunesis Pharmaceuticals, Inc.; and Xencor.
Other Financial or Material Support Nonrelevant Financial Relationship: National Comprehensive Cancer Network (Chair & CLL).

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AbbVie, AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/2/2024. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on July 2, 2024; credit is no longer available.

Defying the Odds With Innovation in CLL: Perspectives on Personalized Care, Multiagent Platforms, and Sequential Strategies

Media: Enduring Material
Activity Release Date: June 3, 2023
Activity Expiration Date: July 2, 2024
Time to Complete Activity: 90 minutes

Activity Description

Learn how the experts “defy the odds” every day by exposing patients with chronic lymphocytic leukemia (CLL) to the clinical benefits of innovative therapy! Novel therapeutics based on BTK and BCL2 inhibitor platforms have radically transformed the management of CLL and allowed for a greater range of treatment options in a range of CLL settings. This MasterClass & Case Forum activity, adapted from a recent live event and developed in collaboration with the CLL Society, offers learners expert guidance on how to select and sequence agents over several lines of therapy while proactively integrating newer BTKi strategies, targeted combination platforms, and cellular immunotherapy into safe, personalized treatment plans. Throughout, learn about offerings from the CLL Society that will help you engage with patients and offer them the resources they need to contribute to care decisions.

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, physician assistants, nurse practitioners, and other clinicians involved in the management of patients with chronic lymphocytic leukemia.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize safety/efficacy evidence and practice guidelines that support the use of novel targeted and emerging immunotherapy agents in CLL, such as BTK and BCL2 inhibitors, CAR-T cells, and bispecifics
• Integrate novel and emerging targeted strategies into personalized single-agent and combination regimens for patients with TN CLL based on prognostic information, the presence of comorbidities, and safety considerations
• Develop appropriate sequential treatment plans with targeted agents and emerging immunotherapy options for patients with therapeutic intolerance and/or R/R CLL
• Implement evidence-based protocols to address the unique safety considerations associated with the use of targeted agents and emerging immunotherapy options in the CLL setting

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Matthew S. Davids, MD, MMSc
Director of Clinical Research, Division of Lymphoma
Dana-Farber Cancer Institute
Co-Leader for Lymphoma of Dana-Farber/Harvard Cancer Center
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Matthew S. Davids, MD, MMSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Genentech, Inc.; Genmab; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Mingsight Pharmaceuticals Inc.; Ono Pharmaceutical Co., Ltd.; Secura Bio; Takeda Pharmaceutical Company Ltd.; and TG Therapeutics, Inc.
Grant/Research Support from AbbVie; Ascentage Pharma; AstraZeneca; Genentech, Inc.; Novartis Pharmaceuticals Corporation; Secura Bio; and TG Therapeutics, Inc.
Honoraria from Aptitude Health; Bio Ascend; and Curio Science.
Other Financial or Material Support in the form of Royalties from Up-to-Date.

Faculty/Planner
Adam Scott Kittai, MD
Assistant Professor – Clinical, Division of Hematology
Department of Internal Medicine
The Ohio State University
Columbus, Ohio

Adam Scott Kittai, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; BeiGene, Inc.; Bristol Myers Squibb; Janssen Pharmaceuticals, Inc.; Kite, A Gilead Company; and Lilly.
Grant/Research Support from AstraZeneca.
Speaker for AbbVie; BeiGene, Inc.; and Bristol Myers Squibb.

Faculty/Planner
Nicole Lamanna, MD
Associate Professor of Medicine
Director of the Chronic Lymphocytic Leukemia Program
Hematologic Malignancies Section
Columbia University Irving Medical Center
Herbert Irving Comprehensive Cancer Center
New York, New York

Nicole Lamanna, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; Adaptive Biotechnologies; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; and Pharmacyclics LLC.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Lilly/Loxo Oncology; MingSight Pharmaceuticals, Inc.; Octapharma USA, Inc.; Oncternal Therapeutics; and TG Therapeutics, Inc.

Faculty/Planner
William G. Wierda, MD, PhD
Professor, Department of Leukemia, Division of Cancer Medicine
D.B. Lane Cancer Research Distinguished Professor
Section Chief - Chronic Lymphocytic Leukemia
Center Medical Director
Executive Medical Director
The University of Texas MD Anderson Cancer Center
Houston, Texas

William G. Wierda, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Grant/Research Support from AbbVie; Acerta Pharma; Bristol Myers Squibb; Cyclacel Pharmaceuticals Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GlaxoSmithKline; Janssen Biotech, Inc.; Juno Pharmaceuticals; Kite, A Gilead Company; Loxo Oncology, Inc.; miRagen Therapeutics, Inc.; Novartis Pharmaceuticals Corporation; Oncternal Therapeutics; Pharmacyclics, Inc.; Sunesis Pharmaceuticals, Inc.; and Xencor.
Other Financial or Material Support Nonrelevant Financial Relationship: National Comprehensive Cancer Network (Chair & CLL).

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AbbVie, AstraZeneca, Bristol Myers Squibb, and Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.5 contact hour(s) and 1.5 contact hour(s) in the area of pharmacology.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until 7/2/2024. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on June 30, 2024; credit is no longer available.

Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition

Media: Enduring Material
Activity Release Date: June 1, 2023
Activity Expiration Date: June 30, 2024
Time to Complete Activity: 60 minutes

Activity Description

Optimal management of multiple sclerosis (MS) requires selecting medications that safely and effectively target different aspects of pathophysiology and offer choices in administration, risk/benefit balance, and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an emerging class of disease-modifying therapies that affect processes mediated by B cells and myeloid cells, which are contributors to the inflammation and neurodegeneration that drive MS. BTK inhibitors are a novel class in MS management with four agents currently in phase 3 trials. As such, clinicians must remain up to date with the latest data on the rationale for their use and trial findings on the efficacy, safety, and tolerability of this promising line of treatment.

At a recent PeerView live event, MS experts shared relevant stories from their practice to highlight the rationale for the use of BTK inhibitors in MS, as well as perspectives on potential applications in clinical care and the latest data from clinical trials on BTK inhibition.

Target Audience

This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other clinicians involved in the care of patients with multiple sclerosis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Explain the rationale for investigating the potential of Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) treatment
• Assess emerging evidence on the risks and benefits associated with BTK inhibitors in late-stage clinical trials for the treatment of MS
• Identify patients who might be candidates for treatment with a BTK inhibitor, based on available data as well as individual patient characteristics and priorities

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Amit Bar-Or, MD, FRCPC
Melissa and Paul Anderson President’s Distinguished Chair
Professor, Department of Neurology
Chief, Division of Multiple Sclerosis and Related Disorders
Director, Centre for Neuroinflammation and Experimental Therapeutics
University of Pennsylvania
Children’s Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania

Amit Bar-Or, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Accure Pharma; Atara Biotherapeutics, Inc.; Biogen; Bristol Myers Squibb/Celgene Corporation/Receptos, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Gossamer Bio; Janssen Pharmaceuticals, Inc./Actelion Pharmaceuticals US, Inc.; Medimmune, LLC; Merck & Co., Inc./EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; and Sanofi Genzyme.
Grant/Research Support from Biogen; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Merck & Co., Inc./EMD Serono, Inc.; and Novartis Pharmaceuticals Corporation (paid to institution).

Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada

Professor Anthony Traboulsee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; F. Hoffmann-La Roche Ltd; Genzyme Corporation; and Novartis Pharmaceuticals Canada Inc.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Genzyme Corporation.
Speaker for F. Hoffmann-La Roche Ltd and Genzyme Corporation.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-014-H01-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on June 30, 2024; credit is no longer available.

Can a Novel DMT Class Deliver Better Outcomes in MS? Considering the Potential of BTK Inhibition

Media: Enduring Material
Activity Release Date: June 1, 2023
Activity Expiration Date: June 30, 2024
Time to Complete Activity: 60 minutes

Activity Description

Optimal management of multiple sclerosis (MS) requires selecting medications that safely and effectively target different aspects of pathophysiology and offer choices in administration, risk/benefit balance, and patient adherence. Bruton tyrosine kinase (BTK) inhibitors are an emerging class of disease-modifying therapies that affect processes mediated by B cells and myeloid cells, which are contributors to the inflammation and neurodegeneration that drive MS. BTK inhibitors are a novel class in MS management with four agents currently in phase 3 trials. As such, clinicians must remain up to date with the latest data on the rationale for their use and trial findings on the efficacy, safety, and tolerability of this promising line of treatment.

At a recent PeerView live event, MS experts shared relevant stories from their practice to highlight the rationale for the use of BTK inhibitors in MS, as well as perspectives on potential applications in clinical care and the latest data from clinical trials on BTK inhibition.

Target Audience

This activity has been designed to meet the educational needs of neurologists, nurses, pharmacists, and other clinicians involved in the care of patients with multiple sclerosis.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Explain the rationale for investigating the potential of Bruton tyrosine kinase (BTK) inhibition in multiple sclerosis (MS) treatment
• Assess emerging evidence on the risks and benefits associated with BTK inhibitors in late-stage clinical trials for the treatment of MS
• Identify patients who might be candidates for treatment with a BTK inhibitor, based on available data as well as individual patient characteristics and priorities

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Amit Bar-Or, MD, FRCPC
Melissa and Paul Anderson President’s Distinguished Chair
Professor, Department of Neurology
Chief, Division of Multiple Sclerosis and Related Disorders
Director, Centre for Neuroinflammation and Experimental Therapeutics
University of Pennsylvania
Children’s Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania

Amit Bar-Or, MD, FRCPC, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Accure Pharma; Atara Biotherapeutics, Inc.; Biogen; Bristol Myers Squibb/Celgene Corporation/Receptos, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Gossamer Bio; Janssen Pharmaceuticals, Inc./Actelion Pharmaceuticals US, Inc.; Medimmune, LLC; Merck & Co., Inc./EMD Serono, Inc.; Novartis Pharmaceuticals Corporation; and Sanofi Genzyme.
Grant/Research Support from Biogen; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Merck & Co., Inc./EMD Serono, Inc.; and Novartis Pharmaceuticals Corporation (paid to institution).

Co-Chair/Planner
Professor Anthony Traboulsee, MD
Research Chair of the MS Society
Division of Neurology, Department of Medicine
The University of British Columbia
Vancouver, British Columbia, Canada

Professor Anthony Traboulsee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Biogen Canada Inc.; F. Hoffmann-La Roche Ltd; Genzyme Corporation; and Novartis Pharmaceuticals Canada Inc.
Grant/Research Support from F. Hoffmann-La Roche Ltd and Genzyme Corporation.
Speaker for F. Hoffmann-La Roche Ltd and Genzyme Corporation.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-0000-23-014-H01-P
Type of Activity: Knowledge

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/NCPD/CPE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 18, 2024; credit is no longer available.

Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management

Media: Enduring Material
Activity Release Date: May 19, 2023
Activity Expiration Date: May 18, 2024
Time to Complete Activity: 30 minutes

Activity Description

In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life.

Target Audience

This activity has been designed to meet the educational needs of infectious disease specialists, respirologists, pulmonologists, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the management of patients with NTM-LD.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis
• Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care
• Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Patrick A. Flume, MD
Distinguished Professor of Medicine and Pediatrics
Medical University of South Carolina
Charleston, South Carolina

Patrick A. Flume, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Aceragen Inc.; Chiesi USA, Inc.; Eloxx Pharmaceuticals, Inc.; Insmed Incorporated; Ionis Pharmaceuticals; Janssen Pharmaceuticals, Inc.; McKesson Corporation; Merck & Co., Inc.; Polyphor; Santhera Pharmaceuticals; and Vertex Pharmaceuticals Incorporated.
Grant/Research Support from AbbVie Inc.; Aceragen Inc.; Armata Pharmaceuticals, Inc.; AstraZeneca; Insmed Incorporated; Janssen Pharmaceuticals, Inc.; Novovax; RedHill Biopharma Ltd; Sound Pharmaceuticals; and Vertex Pharmaceuticals Incorporated.

Co-Chair/Planner
Gwen A. Huitt, MD, MS
Professor, National Jewish Health (Ret.)
Division of Mycobacterial and Respiratory Infections
Denver, Colorado

Gwen A. Huitt, MD, MS, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Susan Palmer

Susan Palmer has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Insmed.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-042-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView

This activity expired on May 18, 2024; credit is no longer available.

Improving the Patient Experience in Nontuberculous Mycobacterial Lung Disease: The Intersection of Early Diagnosis, Customized Therapy, and Adverse Event Management

Media: Enduring Material
Activity Release Date: May 19, 2023
Activity Expiration Date: May 18, 2024
Time to Complete Activity: 30 minutes

Activity Description

In this activity, experts in nontuberculous mycobacterial lung disease discuss diagnosis of the disease through knowledge of risk factors, comorbid conditions, and disease signs and symptoms. Through a collection of short, focused educational modules, the faculty will also discuss managing adverse events and creating personalized care plans to improve patient adherence and outcomes. Interviews with a patient will highlight the impact that NTM-LD—and proper treatment—can have on quality of life.

Target Audience

This activity has been designed to meet the educational needs of infectious disease specialists, respirologists, pulmonologists, nurse practitioners, physician assistants, pharmacists, and other clinicians involved in the management of patients with NTM-LD.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Identify risk factors, comorbid conditions, and signs and symptoms of NTM-LD to facilitate early diagnosis
• Work with the care team to create personalized treatment plans for patients with NTM-LD according to current guidelines and patient goals/preferences, using shared decision-making and evidence-based care
• Employ guideline-based strategies to help patients manage drug-related adverse events/toxicity to improve adherence and treatment outcomes

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by, or used, on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Patrick A. Flume, MD
Distinguished Professor of Medicine and Pediatrics
Medical University of South Carolina
Charleston, South Carolina

Patrick A. Flume, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Aceragen Inc.; Chiesi USA, Inc.; Eloxx Pharmaceuticals, Inc.; Insmed Incorporated; Ionis Pharmaceuticals; Janssen Pharmaceuticals, Inc.; McKesson Corporation; Merck & Co., Inc.; Polyphor; Santhera Pharmaceuticals; and Vertex Pharmaceuticals Incorporated.
Grant/Research Support from AbbVie Inc.; Aceragen Inc.; Armata Pharmaceuticals, Inc.; AstraZeneca; Insmed Incorporated; Janssen Pharmaceuticals, Inc.; Novovax; RedHill Biopharma Ltd; Sound Pharmaceuticals; and Vertex Pharmaceuticals Incorporated.

Co-Chair/Planner
Gwen A. Huitt, MD, MS
Professor, National Jewish Health (Ret.)
Division of Mycobacterial and Respiratory Infections
Denver, Colorado

Gwen A. Huitt, MD, MS, has no financial interests/relationships or affiliations in relation to this activity.

Patient/Planner
Susan Palmer

Susan Palmer has no financial interests/relationships or affiliations in relation to this activity.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Insmed.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.25 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-23-042-H01-P
Type of Activity: Application

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD) (required for all Boards except ABA, ABP, and ABS), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2023, PeerView